GenSpera, Inc.

Corporate Snapshot

GenSpera, Inc. ("GenSpera" or "the Company") is a biotechnology company developing targeted therapies to treat cancerous tumors. The Company's novel approach uses a prodrug—an inactive precursor of a drug that converts into its active form at a targeted site—to deliver a potent, cell-killing agent directly to tumors. GenSpera's prodrugs employ one of two techniques: (1) targeting tumor-associated blood vessels; or (2) targeting tumors directly. In contrast to existing anti-angiogenic drugs, which may only block new blood vessel formation, the Company's lead prodrug candidate, G-202, attacks existing tumor vasculature, potentially debilitating the tumor's nutrient supply and causing cancer regression without toxicity to other areas of the body. G-202 has caused tumor regression in animal models of breast, prostate, bladder, and kidney cancer. A Phase I clinical trial with G-202 is ongoing at two major cancer centers. GenSpera's technology can also be used to attack cancer cells directly by targeting the prodrug to enzymes found solely at tumor sites. Using this approach, GenSpera is developing G-115, which targets prostate cancer. The Company owns and controls all rights to G-202 and G-115 and seeks a strategic partnership to maximize the value of these prodrugs. GenSpera has headquarters in San Antonio, Texas, and trades on the Over-the-Counter Bulletin Board (OTC.BB) as "GNSZ."